Business
Press Release (Revised) Feb 05 2026
Strides Pharma Science Limited has informed the Exchange regarding a revised press release dated February 05, 2026, titled "Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility at Chestnut Ridge, New YorkInspection included Drug Device Combinations covering our recent filing in Nasal Sprays domain".
About this update from Strides Pharma Science Ltd
Strides Pharma Science Limited has informed the Exchange regarding a revised press release dated February 05, 2026, titled "Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility at Chestnut Ridge, New YorkInspection included Drug Device Combinations covering our recent filing in Nasal Sprays domain". View Attachment
View stock analysis, news, and events for Strides Pharma Science Ltd